I-composable injini inganciphisa ubuhlungu be-osteoarthritis esandulelayo
I-Synvisc (i-hylan GF 20) i-fluctuous viscous etholakala ebizwa ngokuthi i- hyaluronan (i-hyaluronate ye-sodium). I-Hyaluronan ikhiqizwa ngokwemvelo emzimbeni ukusiza ukugcoba amalunga. Ifomu elitholakala ku-Synvisc lenziwe ngezinto ezisetshenziswa yi-gelatinous ezitholakala emanzini enkukhu.
I-synvisc isetshenziswe ngendlela yokwelashwa eyaziwa ngokuthi i- viscosupplementation lapho i-substance ijojelwe khona ezindaweni ezihlangene ukuze kusize ukwandisa ukugcoba.
Ukubukwa kwezidakamizwa
Amagciwane e-synvisc avunyelwe ukwelashwa kwe- osteoarthritis yamadolo kubantu abahlulekile ukuphendula ukwelashwa okunamandla okunye, kufaka phakathi ama- analgesics nezinketho ezingezona izidakamizwa.
I-Synvisc inikezwa umjovo we-milliliter ngokuqondile emadolweni. Ayikavunyelwanga nganoma yikuphi okuhlangene ngaphandle kwedolo. I-synvisc ivame ukunikezwa njengochungechunge lwemijovo emithathu evezwa njalo njalo ngesonto. Ukuze uzuze imiphumela emihle, amanzi e- synovial emgodini wamadolo ngokuvamile asuswe ngaphambi kokujola kokuqala.
Kukhona omunye umkhiqizo we-synvisc, owaziwa ngokuthi i-Synvisc-One, ephathwa njengokudubula okukodwa, okungama-millilitha.
I-Synvisc yavunyelwa ukuthi isebenziswe yi-US Food Administration and Drug Administration ngo-Agasti 8, 1997. I-Synvisc-One yamukelwa imvume ye-FDA ngoFebhuwari 26, 2009. Imiphumela emibi kakhulu ehambisana neS Synvisc ihlanganisa:
- Ubuhlungu, ukuvuvukala, noma ukuqina emgodleni ojowe
- Ukuxuba okuhlangene ("amanzi emadolweni")
- Ubuhlungu bomzimba obuhlangene
- Rash noma imifantu
- Fever
- I-nausea
- Izinwele
- Isizungu
- Ama-cramp muscle
- Ukukhathala
Iningi lalezi zimpawu zisezingeni eliphansi ukuze zilinganise ngokweqile futhi zizozixazulula zodwa ngaphandle kokwelashwa. Uma kukhona izimpawu eziqhubekayo noma ezimbi, shayela udokotela wakho ngokushesha ngoba lokhu kungase kube uphawu lokutheleleka noma ukungezwani komzimba.
Ukusebenza kwe-synvisc ekunqandeni ukuhlinzwa kokuhlinzwa
Icwaningo lomtholampilo lwenziwa ukuze kuhlolwe ukusebenza kwe-synvisc kubantu abane-osteoarthritis ephakeme yamadolo owodwa noma womabili. Abahlanganyeli bahlanganisa abesifazane abangama-56 namadoda angu-52 abaneminyaka yobudala engama-62. Ngamunye uhlulekile ukuthola ukukhululeka ngezidakamizwa ezingekho emthethweni ezingenakuvuvukala (ama-NSAID) noma ama- cortisone shots .
Ngesikhathi socwaningo, umhlanganyeli ngamunye wathola injection ye-Synvisc ezintathu ngesonto ngaphandle. Ukuhlolwa kwenziwa kwinye, ezintathu, eziyisithupha, 12, 15 nezinyanga ezingu-18. Lolu cwaningo luhlose ukuhlola ukuhlushwa okubonakalayo phakathi kwabahlanganyeli bezokucwaninga bese ubeka ukuthi ukwelashwa okusemandleni kwakungokulibala kanjani ukuguqulwa kwama-knee esikhundleni (TKR) .
Lapho sekuphelile, abacwaningi babembule ukuthi iziguli ezingu-72.6 zamaphesenti eziphathwa nge-Synvisc yokugwetshwa kwe-TKR kulo lonke isifundo. Yize kungekho miphumela emibi kakhulu noma ehlala isikhathi eside, kubonakala ukuthi abantu abayisishiyagalombili babhekana nokuphendula okunamandla okulandela ukujola. Akukho okubhekwa njengokubalulekile.
Ngokusekelwe eNtshonalanga Ontario naseMcMaster Amanyuvesi Osteoarthritis Index ( WOMAC ), ukuhlolwa okusetshenziselwa ukukala amazinga obuhlungu abuzwayo, abantu abakwaS Synvis bahlangabezana namaphesenti angaba ngu-20 bewela ebuhlungu uma kuqhathaniswa nalabo abasendaweni ye-placebo.
I-osteoarthritis yamadolo namuhla yiyona ndlela ejwayelekile kakhulu ye-arthritis e-United States, ethinta abantu abangaba ngu-13.7 million. Ngokusekelwe ekutholeni okufundwayo, i-Synvisc ibhekwa njengendlela ephephile futhi ephumelelayo yokwelapha ubuhlungu nokukhubazeka kule ndawo futhi, uma isetshenziswe ngokufanele, ingasiza ukuhlinzekwa ukulibazisa iminyaka emithathu noma ngaphezulu.
> Umthombo:
> Ukuphathwa Kwezokudla Nezidakamizwa zase-US. (2008) "Isifinyezo se-Synvisc-One sokuphepha nokusebenza." I-Silver Spring, e-Maryland.